EMG
RPRX icon

ETF Managers Group’s Royalty Pharma RPRX Stock Holding History

ETF Managers Group’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		$436K Buy
+12,103
New +$449K 0.01% 479

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ETF Managers Group's RPRX Position: Q1 2023 in Review

ETF Managers Group opened a new position in Royalty Pharma (RPRX) in Q1 2023: 12,103 shares worth $436K. The stake represents 0.01% of the portfolio and ranks #479 among its holdings.

335 funds tracked by Wall St. Rank hold RPRX as of Q1 2023.

  • ETF Managers Group held 12,103 shares of Royalty Pharma worth $436K as of Q1 2023.
  • Royalty Pharma was a new ETF Managers Group position in Q1 2023.
  • Royalty Pharma made up 0.01% of ETF Managers Group's portfolio in Q1 2023, its #479 holding.
  • 335 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2023.

Based on ETF Managers Group's 13F filing for Q1 2023, filed 18 Apr 2023.